Funded Biotechnology Startups in Seattle
Seattle's biotechnology cluster has generated funding rounds at every stage between June 2021 and October 2025, from a $300K close by BrainChild Bio in Jan…
Seattle's biotechnology cluster has generated funding rounds at every stage between June 2021 and October 2025, from a $300K close by BrainChild Bio in January 2025 to Callio Therapeutics' $187M Series A two months later. The two most recent entries — Lumen Bioscience's $30M Series C on October 7, 2025, and Singletto's $10M Series A the day prior — cap a list that also includes Tune Therapeutics' $175M Series B and Umoja Biopharma's $100M Series C, both closed in January 2025.
Funding structures extend beyond standard equity: the Allen Institute for Brain Science received a $173M grant in September 2022, and Adaptive Biotechnologies drew $125M in post-IPO debt financing the same month. A significant share of rounds carry a "Series Unknown" designation despite substantial capital raised — Sana Biotechnology ($86M, August 2025) and Alpine Immune Sciences ($150M, November 2023) are among the more prominent examples.
Most recent rounds
50 shownRelated listings
Frequently asked
Which Seattle biotech companies raised the largest disclosed rounds in this cohort?
The five largest are Callio Therapeutics at $187M (Series A, March 2025), Tune Therapeutics at $175M (Series B, January 2025), the Allen Institute for Brain Science at $173M via grant (September 2022), GentiBio at $157M (Series A, August 2021), and Alpine Immune Sciences at $150M (Series Unknown, November 2023).
Which companies show Series B or later rounds in the data?
Series B companies include Tune Therapeutics ($175M), Outpace Bio ($144M), Shape Therapeutics ($112M), ProfoundBio ($112M), Cyrus Biotechnology ($18M), Proniras Corp ($5M), and KitoTech Medical ($2M). At Series C or above: Umoja Biopharma ($100M Series C), Parse Biosciences ($50M Series C), Lumen Bioscience ($30M Series C), and Avalyn Pharma ($100M Series D).
Are there unusually large Series A rounds in this data?
Callio Therapeutics' $187M Series A (March 2025) and GentiBio's $157M Series A (August 2021) are both atypically large for the label. InduPro raised $85M at Series A in June 2024, and Bonum Therapeutics closed $93M at Series A in November 2022, also well above typical Series A benchmarks.
What does seed-stage activity look like among these Seattle biotech companies?
Four companies carry seed designations: Monod Bio at $25M (August 2022), Talus Bio at $11M (August 2024), Genemod at $5M (May 2023), and ZipBio at $4M (September 2024). Monod Bio's $25M seed is the largest of the group by a wide margin.
What non-equity funding structures appear alongside the venture rounds?
Three non-equity structures are present: grants (Allen Institute for Brain Science at $173M in September 2022; Blue Marble Space Institute of Science at undisclosed in July 2022), post-IPO debt (Adaptive Biotechnologies at $125M in September 2022), and debt financing (Visus Therapeutics at $20M in August 2021; SiDx at $300K in October 2021).
How active has Seattle biotech funding been in 2025 based on the rounds shown?
Eleven rounds are dated in 2025, ranging from BrainChild Bio's $300K close in January to Sana Biotechnology's $86M raise in August. The two largest — Callio Therapeutics at $187M (March) and Tune Therapeutics at $175M (January) — are followed by a pair of $100M closes: Umoja Biopharma in January and Avalyn Pharma in July.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.